CheckMate 204 Results Are ‘Practice-Changing’ for Melanoma Patients With Brain Mets

Source: Medscape, May 2019

This transcript has been edited for clarity.

Hello. I am Dr Jeffrey Weber. I’m deputy director of and a medical oncologist at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Health in New York City. Today I will be discussing a very interesting study that was recently reported in the New England Journal of Medicine.^[1]

CheckMate 204 combined the immunologic drugs ipilimumab and nivolumab, the CTLA4 and PD-1 blocking antibodies, for treatment of patients with metastatic melanoma with brain metastases at first presentation. We have discussed preliminary data from this study, CheckMate 204, which were presented at the 2017 ASCO meeting, but now we have this more definitive report.